Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions.
about
Therapy of human papillomavirus-related diseaseCell-mediated immune response to human papillomavirus infection.Tumor-infiltration of T-lymphocytes is inversely correlated with clinicopathologic factors in endometrial adenocarcinoma.Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome.Immunotherapy of human papilloma virus induced diseaseRole of zinc and alpha2 macroglobulin on thymic endocrine activity and on peripheral immune efficiency (natural killer activity and interleukin 2) in cervical carcinomaExpression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodesLack of MHC class I surface expression on neoplastic cells and poor activation of the secretory pathway of cytotoxic cells in oral squamous cell carcinomas.Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable.Blessing or curse? Proteomics in granzyme research.Increased expression of PD‑L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunityHigh levels of granzyme B expression in invasive cervical carcinoma correlates to poor response to treatment.Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.The cellular response associated with cervical intraepithelial neoplasia in HIV+ and HIV- subjects.Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma.Distinct T cell subsets and cytokine production in cultures derived from transformation zone and squamous intraepithelial lesion biopsies of the uterine cervix.Vaccinations for Anal Squamous Cancer: Current and Emerging Therapies
P2860
Q27007473-EDFD5734-3BF6-4DCD-B513-849461593E9BQ33998922-53BD5195-ACAB-4077-BE4F-3401A52F2183Q34011765-2467D82C-728F-4072-B35E-3DEE0912015DQ35784867-4B2CC218-1A1C-4511-8918-7B64DCF513ACQ36050315-957262F5-E813-4770-BED3-984135F00D06Q36541008-07E5B7E1-DB27-451D-B826-6D8575EC515DQ36617408-46CE65EC-C958-4470-8198-68618BF0C9EDQ36617463-9EF9AC27-5C83-425F-A153-46F1B4AC0487Q36640998-D3FBE591-25EC-4FD2-B805-EEC7E8B33A9FQ36746876-927CAC4A-8723-4A0B-AE31-F4E4A3878A6FQ38200060-3D21D792-EE33-43CF-B329-A6FA80FD4854Q38721959-847A39DA-E748-4407-9B1A-E52480F95979Q43514433-CC3E771A-4FA2-4FBC-B672-3C8B2C6C5ABCQ44143986-0D060802-E010-4032-9C06-2432C281D106Q44549174-2002D768-F877-4436-AB33-F7BAE985D91DQ44876069-A028A52A-EC26-434E-B35B-A4C0F4E53BD6Q53379799-4D6ACA10-CF1E-4786-B9C4-E29D798E16FBQ58548093-88107653-25EA-411E-8857-B98C11059203
P2860
Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Assessment of cytotoxic T-lymp ...... n cervical neoplastic lesions.
@ast
Assessment of cytotoxic T-lymp ...... n cervical neoplastic lesions.
@en
type
label
Assessment of cytotoxic T-lymp ...... n cervical neoplastic lesions.
@ast
Assessment of cytotoxic T-lymp ...... n cervical neoplastic lesions.
@en
prefLabel
Assessment of cytotoxic T-lymp ...... n cervical neoplastic lesions.
@ast
Assessment of cytotoxic T-lymp ...... n cervical neoplastic lesions.
@en
P2093
P2860
P356
P1476
Assessment of cytotoxic T-lymp ...... n cervical neoplastic lesions.
@en
P2093
Bontkes HJ
Gunther AW
Scheper RJ
Walboomers JM
de Gruijl TD
van den Muysenberg AJ
P2860
P2888
P304
P356
10.1038/BJC.1997.560
P407
P577
1997-01-01T00:00:00Z
P5875
P6179
1015414274